Radiologic study of the nasal septal swell body and its relationship to septal deviation

Objective@#To compare the radiographic features of the nasal septal swell body (NSB) with the laterality of nasal septal deviation and investigate whether there is a correlation between the severity of the septal deviation and difference in NSB size.@*Methods@#Design: Retrospective Observational Study. Setting: Tertiary Private University Hospital. Participants: 30 paranasal sinus computerized tomography scans from January to October 2017.@*Results@#A septal deviation was present in 60% of the subjects. In 78% of cases with septal deviation, the NSB was noted to be significantly larger on the side opposite the nasal septal deviation (p < .05). @*Conclusion@#The correlation between the severity of the septal deviation and difference in NSB size had a value of (r = 0.37) therefore, no positive correlation was established. Subjects with almost symmetric NSB measurements tend to have no septal deviation. On the other hand, the NSB is more prominent contralateral to a septal deviation.

Peripheral T-cell lymphoma presenting as an auricle mass

@#<p class="MsoNormal"> </p><p class="MsoNormal" style="text-align: justify; text-indent: .5in;">When evaluating patients with a non-traumatic auricular deformity that presents like a soft tissue infection unresponsive to antibiotic therapy and progressively resembles a tumor, immediate biopsy and imaging should be instituted to obtain an accurate diagnosis and avoid unnecessary procedures. After all, not all head and neck masses are managed with surgery. </p><p class="MsoNormal" style="text-align: justify;"><b> </b></p><p class="MsoNormal" style="text-align: center;" align="center"><b>CASE REPORT</b></p><p class="MsoNormal" style="text-align: justify; text-indent: .5in;">A 64-year-old diabetic man with a 30 pack-year smoking history presented with progressive diffuse swelling of the right auricule with exudative yellow non-foul smelling discharge. Initially diagnosed with auricular cellulitis by an ENT specialist, there was no response to oral and topical antibiotic treatment as the swelling developed into a large cauliflower-like deformity. Incisional biopsy only revealed fibrocollagenous tissue with chronic inflammation without evident granuloma. </p><p class="MsoNormal" style="text-align: justify; text-indent: .5in;">With the progressively enlarging right auricular mass unresponsive to medical treatment for over six months, the man underwent a series of multi-disciplinary consultations in our institution. Also noted were left tragal enlargement without ulceration or bleeding, palpable level II-III cervical lymph nodes (measuring 2.5 cm in widest diameter), but no palpable skin lesions, other signs or associated symptoms. (Figure 1) Otoscopy was normal with normal hearing thresholds on the right and mild conductive hearing loss on the left on pure tone audiometry. The rest of the physical examination and blood laboratory tests were unremarkable. </p><p class="MsoNormal" style="text-align: justify; text-indent: .5in;">A temporal bone CT scan (to determine mass extent and the best site for repeat incisional biopsy) showed an intensely enhancing external ear mass extending to the outer cartilaginous portion of the auditory canal with multiple sub-centimeter enhancing nodules in the right parotid gland. (Figure 2) An excision biopsy between the junction of the mass and grossly normal-looking tissue of the right helix revealed Atypical Round Cell Tumor, subsequently diagnosed as T-cell Lymphoma after strongly staining with CD3 and Ki67 immunohistochemistry studies. </p><p class="MsoNormal" style="text-align: justify; text-indent: .5in;">After unremarkable repeat chest x-ray and abdominal CT findings, the patient underwent six cycles of chemotherapy using the CHOP (Doxorubicin, Vincristine, Cyclophosphamide, Prednisone) protocol for Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), Stage II. Significant decrease in size of the auricular mass was noted from the second cycle until no mass was evident after completion of the regimen. No recurrence was noted during a 48-month follow-up period. (Figure 3) </p><p class="MsoNormal" style="text-align: justify;"><b> </b></p><p class="MsoNormal" style="text-align: center;" align="center"><b>DISCUSSION</b></p><p class="MsoNormal" style="text-align: center;" align="center"> </p><p class="MsoNormal" style="text-align: justify; text-indent: .5in;">Because the external ear and auditory canal can be affected by various organisms especially in elderly, diabetic, and immunocompromised individuals, aggressive medical treatment is often warranted. A neoplastic etiology should be suspected when rapidly progressive ear deformities arise in cases of perichondritis and other non-infectious inflammatory conditions that are non-responsive even to culture-guided therapy. In the absence of trauma, such other causes of ear deformity as sarcoidosis, perniosis, polychondritis, and auricular pseudocyst must be carefully investigated by adequate biopsies and histopathologic studies to rule out malignant processes.1,2</p><p class="MsoNormal" style="text-align: justify; text-indent: .5in;">Lymphomas represent approximately 2.5% of head and neck malignancies, and the majority present with cervical lymph node involvement.2 While 40% of head and neck lymphomas occur in such extranodal sites as the nasopharynx, lacrimal sac, temporal bone, or salivary glands, they rarely involve the auricle and external auditory canal.2 More common malignancies that may lead to auricular masses and deformities such as squamous cell carcinoma, adenocarcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, basal cell carcinoma, and rhabdomyosarcoma, must be ruled out.3,4 These conditions have distinct presentations and may arise from the external ear, middle ear or temporal bone before affecting the external auditory canal.5</p><p class="MsoNormal" style="text-align: justify; text-indent: .5in;">The literature on extra-nodal lymphomas is scarce, with B- cell origin more commonly reported. On the other hand, peripheral T-cell lymphomas (PTCL) represent only 10-15% of non-Hodgkin lymphoma, categorized as nodal, extra nodal or leukemic.6 A subtype of PTCL that do not correspond to any of the specifically defined T-cell entities in the World Health Organization (WHO) classification are defined as not otherwise specified PCTL (PTCL-NOS).7,8 However, based on a search of PubMed and HERDIN using the search terms "peripheral T-cell lymphoma," "auricle," and "external ear," to the best of our knowledge, PTCL-NOS has not been locally reported as primarily affecting the external ear.6,8 </p><p class="MsoNormal" style="text-align: justify; text-indent: .5in;">The clinical presentation of primary lymphomas of the EAC is non-specific and they can be easily misdiagnosed and treated as infectious or inflammatory conditions of the external ear. As with other conditions, early and accurate diagnosis based on good clinical correlation with imaging studies must be achieved to allow early and specific treatment. For PTCL-NOS, the Ann Arbor staging system still applies although it was originally designed for Hodgkin lymphoma.7 Surgical management has been reported for isolated auricular lymphomas but disseminated disease or involvement of complex structures such as the external ear warrant chemotherapy as the primary and definitive treatment.2 External beam radiation has likewise been reported as an option but may not be applicable in this particular case where structural preservation of the auricle is considered.2 To date, no therapeutic guidelines have been established due to the paucity of cases.</p><p class="MsoNormal" style="text-align: justify; text-indent: .5in; line-height: 200%;"> </p><p class="MsoNormal" style="text-align: justify; text-indent: .5in;">This case of PTCL-NOS of the auricle, just like other reported cases of lymphoma arising from the external auditory canal, appear to respond well with the standard CHOP regimen.  The favorable resolution in our case suggests that surgical resection of the auricle should be reserved for non-response to standard treatment for lymphoma. </p>